Group 1 - The top three companies with the highest short positions as of August 29 are ZTE Corporation (00763) at 16.47%, COSCO Shipping Holdings (01919) at 13.94%, and CATL (03750) at 13.88% [1][2] - The company with the largest increase in short positions is Ganfeng Lithium (01772), which rose by 2.85% to 12.46% [2][3] - The companies with the largest decrease in short positions include Hisense Home Appliances (00921), which decreased by 3.57% to 4.72%, and WuXi AppTec (02359), which decreased by 2.44% to 11.64% [3][4] Group 2 - The latest short position data shows that the top ten companies with the highest short ratios include China Ping An (02318) at 12.58% and Zijin Mining (02899) at 11.91% [2] - The companies with the most significant increases in short positions also include Huahong Semiconductor (01347) with an increase of 2.56% to 9.73% and Meitu (01357) with an increase of 1.80% to 4.85% [2] - The companies with the most significant decreases in short positions also include Weimob (02013) with a decrease of 1.66% to 9.40% and Linklogis Technology (09959) with a decrease of 1.43% to 2.76% [3][4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 绿叶制药集团有限公司 呈交日期: 2025年9月3日 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02186 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 | 本月底法定/註冊股本總額： U ...

Group 1 - The Hong Kong innovative drug sector continues to rise, with the Hang Seng Innovative Drug Index up by 3.0% as of 10:48, and notable gains in stocks such as Innovent Biologics up over 6%, CanSino Biologics and CSPC Pharmaceutical Group up over 5% [1] - The Hang Seng Innovative Drug ETF (159316) has seen a trading volume exceeding 400 million yuan, with net inflows for four consecutive trading days, bringing its latest scale to 1.8 billion yuan [1] - The National Healthcare Security Administration has officially announced the preliminary review list of drugs for the 2025 medical insurance and commercial insurance innovative drug directory, featuring new drugs including the "million-dollar cancer drug" CAR-T products and several "first and only in the world" products [1] Group 2 - CITIC Securities anticipates a significant increase in innovative drug catalyst events in September, and the recent technology switch has alleviated the short-term speculative money previously accumulated in the sector, suggesting that innovative drugs may continue to rise after this adjustment [1] - The Hang Seng Innovative Drug Index has officially adjusted to exclude contract research organizations (CROs), achieving a "100% purity" index that more accurately reflects the overall performance of China's innovative drug companies [1] - Backtesting indicates that since the index's launch on July 10, 2023, the annualized return and Sharpe ratio have improved after excluding CROs, making the Hang Seng Innovative Drug ETF (159316) the only product tracking this index, aiding investors in precisely positioning themselves for opportunities in the innovative drug industry [1]

于报告期内，本集团在肿瘤治疗领域的收入增加13.5%，达12.95亿元。中枢神经系统治疗领域的收入增 加5.4%，达8.68亿元。心血管系统治疗领域的收入减少9.2%，为6.93亿元。代谢治疗领域的收入减少 7.9%，为1.8亿元。 绿叶制药（02186）绩后涨超5%，截至发稿，股价上涨5.69%，现报3.53港元，成交额1.80亿港元。 8月28日，绿叶制药发布截至2025年6月30日止6个月中期业绩，该集团取得收入人民币31.81亿元（单位 下同），同比增加3.46%；母公司拥有人应占溢利3.13亿元，同比减少19.33%；每股盈利8.32分。 来源：新浪港股 ...

Core Insights - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5%, reaching HKD 3.52 with a trading volume of HKD 93.39 million following the release of its interim results [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 3.181 billion, a year-on-year increase of 3.46% [1] - The profit attributable to the parent company was RMB 313 million, reflecting a year-on-year decrease of 19.33% [1] - Earnings per share stood at 8.32 cents [1] Market Segmentation - In the Chinese market, the company holds a competitive position in four major therapeutic areas: oncology, central nervous system, cardiovascular, and metabolism [1] - The main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolism drugs [1] Revenue Breakdown by Therapeutic Area - Revenue from the oncology segment increased by 13.5%, reaching RMB 1.295 billion [2] - Revenue from the central nervous system segment grew by 5.4%, totaling RMB 868 million [2] - Revenue from the cardiovascular segment decreased by 9.2%, amounting to RMB 693 million [2] - Revenue from the metabolism segment declined by 7.9%, totaling RMB 180 million [2]

Core Viewpoint - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5% following the release of its interim results for the six months ending June 30, 2025, with a reported revenue of RMB 3.181 billion, reflecting a year-on-year increase of 3.46% [1][2] Financial Performance - The company reported a profit attributable to shareholders of RMB 313 million, a decrease of 19.33% year-on-year [1] - Earnings per share were reported at 8.32 cents [1] Revenue Breakdown by Therapeutic Area - Revenue in the oncology treatment sector increased by 13.5%, reaching RMB 1.295 billion [2] - Revenue in the central nervous system treatment sector grew by 5.4%, totaling RMB 868 million [2] - Revenue in the cardiovascular treatment sector decreased by 9.2%, amounting to RMB 693 million [2] - Revenue in the metabolic treatment sector declined by 7.9%, reaching RMB 180 million [2] Product Portfolio - The company's main products in China include six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolic drugs [1] - Internationally, the company focuses on central nervous system treatments, offering various formulations and delivery methods [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) reported a revenue increase of 3.5% year-on-year to RMB 3.181 billion for the six months ending June 30, 2025, while shareholder profit decreased by 19.3% to RMB 313 million [1] Financial Performance - Revenue increased by 3.5% to RMB 3.181 billion [1] - Shareholder profit decreased by 19.3% to RMB 313 million [1] - EBITDA increased by 4.2% to RMB 1.204 billion [1] - Earnings per share stood at RMB 0.0832 [1]

Core Insights - The company reported a revenue of RMB 3.181 billion for the six months ending June 30, 2025, representing a year-on-year increase of 3.46% [1] - The profit attributable to the parent company was RMB 313 million, a decrease of 19.33% year-on-year, with earnings per share at 8.32 cents [1] - The company maintains a competitive position in four major therapeutic areas in the Chinese market: oncology, central nervous system, cardiovascular, and metabolism [1] Revenue Breakdown - Revenue from the oncology segment increased by 13.5% to RMB 1.295 billion [2] - Revenue from the central nervous system segment rose by 5.4% to RMB 868 million [2] - Revenue from the cardiovascular segment decreased by 9.2% to RMB 693 million [2] - Revenue from the metabolism segment declined by 7.9% to RMB 180 million [2] Product Portfolio - The company's main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolism drugs [1] - In the international market, the company's products are primarily focused on the central nervous system treatment area [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. | 截 | 至6月30日止六個月 | 2025年 | 2024年 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | （未 | 經 | 審 | 核） | （未 | 經 | 審 | 核） | 人民幣千元 | 附 | 人民幣千元 | 註 | | 收 | 入 | 3,181,110 | 3,074,582 | 4 | 銷售成本 | (1,023,501) | (996,032) | | | | | | 毛 | 利 | 2,157,609 | 2,078,550 | | | | | | | | | | 197,797 | 202,931 | 其他收入及收益 | 銷售及分銷開 ...

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]